News
CERS
3.120
+0.65%
0.020
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q4 2022 Update
Seeking Alpha · 1d ago
BTIG Downgrades Cerus to Neutral
Benzinga · 01/20 15:17
--BTIG Downgrades Cerus to Neutral From Buy
--BTIG Downgrades Cerus to Neutral From Buy
MT Newswires · 01/20 11:14
S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher
Benzinga · 01/09 19:27
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga · 01/09 18:42
EBON, TMPO and HKD among mid-day movers
Seeking Alpha · 01/09 17:56
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 01/09 17:30
Nasdaq Surges Over 200 Points; Crude Oil Rises 2%
Benzinga · 01/09 17:07
Cerus sheds 19% after issuing 2023 guidance
Seeking Alpha · 01/09 16:08
Cerus Reports Preliminary Q4, 2022 Product Revenue; Issues 2023 Guidance; Shares Fall
Cerus Reports Preliminary Q4, 2022 Product Revenue; Issues 2023 Guidance; Shares Fall
MT Newswires · 01/09 10:13
Cerus's Return On Capital Employed Overview
Benzinga · 11/21/2022 14:48
Cerus Corporation to Participate in Upcoming Investor Conferences
CONCORD, Calif., November 04, 2022--Cerus Corporation (Nasdaq: CERS) announced today that Vivek Jayaraman, Cerus’ chief operating officer, is scheduled to participate in two conferences:
Business Wire · 11/04/2022 12:00
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of 0% and 1.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03/2022 21:55
Cerus GAAP EPS of -$0.05 beats by $0.01, revenue of $46.34M beats by $6.22M
Seekingalpha · 11/03/2022 20:33
Cerus Q3 EPS $(0.05) Beats $(0.06) Estimate, Sales $39.57M Miss $44.55M Estimate
Benzinga · 11/03/2022 20:01
Cerus Corporation Announces Third Quarter Financial Results
CONCORD, Calif., November 03, 2022--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2022.
Business Wire · 11/03/2022 20:00
-- Earnings Flash (CERS) CERUS CORPORATION Posts Q3 Revenue $46.3M, vs. Street Est of $40.6M
-- Earnings Flash (CERS) CERUS CORPORATION Posts Q3 Revenue $46.3M, vs. Street Est of $40.6M
MT Newswires · 11/03/2022 16:09
Cerus Gets $9.1 Million Funding to Develop Product for Trauma-Related Bleeding
Cerus Gets $9.1 Million Funding to Develop Product for Trauma-Related Bleeding
MT Newswires · 11/02/2022 14:39
Health Canada approves extended shelf life for Cerus' blood system treated platelets
Seekingalpha · 11/01/2022 13:19
More
Webull provides a variety of real-time CERS stock news. You can receive the latest news about Cerus through multiple platforms. This information may help you make smarter investment decisions.
About CERS
Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.